BACKGROUND: Systematic investigations assessing the clinical impact of human parechovirus (HPeV) disease are sparse. Noninvasive stool samples may be useful for targeted hospital-based surveillance. METHODS: In the context of a quality management program, all hospitalized children fulfilling predefined case criteria for central nervous system (CNS) infection/inflammation underwent standardized neurologic examinations. Stool samples were collected for HPeV and enterovirus (EV) polymerase chain reaction and molecular typing at the National Reference Center. RESULTS: From October 2010 to December 2012, stool samples of 284 patients with suspected CNS infection/inflammation were tested yielding 12 (4.2%) HPeV+ samples and 43 (15.1%) EV+ samples. HPeV-positive samples included HPeV-1, HPeV-3 and HPeV-6. No additional pathogens were identified in routine care. HPeV-positive patients were significantly younger (P < 0.001) and more likely to present with seizures (P = 0.001) and rash (P < 0.0001) when compared with HPeV-negative patients. CONCLUSIONS: In hospitalized children younger than 4 years presenting with suspected CNS infection/inflammation, seizures and/or rash, HPeV should be considered in the differential diagnosis. Large-scale public health surveillance may be indicated.
BACKGROUND: Systematic investigations assessing the clinical impact of human parechovirus (HPeV) disease are sparse. Noninvasive stool samples may be useful for targeted hospital-based surveillance. METHODS: In the context of a quality management program, all hospitalized children fulfilling predefined case criteria for central nervous system (CNS) infection/inflammation underwent standardized neurologic examinations. Stool samples were collected for HPeV and enterovirus (EV) polymerase chain reaction and molecular typing at the National Reference Center. RESULTS: From October 2010 to December 2012, stool samples of 284 patients with suspected CNS infection/inflammation were tested yielding 12 (4.2%) HPeV+ samples and 43 (15.1%) EV+ samples. HPeV-positive samples included HPeV-1, HPeV-3 and HPeV-6. No additional pathogens were identified in routine care. HPeV-positive patients were significantly younger (P < 0.001) and more likely to present with seizures (P = 0.001) and rash (P < 0.0001) when compared with HPeV-negative patients. CONCLUSIONS: In hospitalized children younger than 4 years presenting with suspected CNS infection/inflammation, seizures and/or rash, HPeV should be considered in the differential diagnosis. Large-scale public health surveillance may be indicated.
Authors: Christian Hoppe; Patrick Obermeier; Susann Muehlhans; Maren Alchikh; Lea Seeber; Franziska Tief; Katharina Karsch; Xi Chen; Sindy Boettcher; Sabine Diedrich; Tim Conrad; Bron Kisler; Barbara Rath Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Kevin Messacar; Marc Fischer; Samuel R Dominguez; Kenneth L Tyler; Mark J Abzug Journal: Infect Dis Clin North Am Date: 2017-12-08 Impact factor: 5.982
Authors: Claire M Midgley; Mary Anne Jackson; Rangaraj Selvarangan; Patrick Franklin; Elizabeth L Holzschuh; Jennifer Lloyd; Joseph Scaletta; Anne Straily; Sheri Tubach; Ashley Willingham; W Allan Nix; M Steven Oberste; Christopher J Harrison; Charles Hunt; George Turabelidze; Susan I Gerber; John T Watson Journal: J Pediatric Infect Dis Soc Date: 2018-05-15 Impact factor: 3.164